Naive CD4+T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ROR1-CAR T Cells

被引：0
|
作者：
Hudecek, Michael [1 ]
Lupo-Stanghellini, Maria-Teresa [1 ]
Kosasih, Paula [1 ]
Bet, Jeannette [1 ]
Paszkiewicz, Paulina [1 ]
Maloney, David G. [1 ]
Jensen, Michael C. [2 ]
Rader, Christoph [3 ]
Riddell, Stanley R. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Seattle Childrens Res Inst, Ctr Childhood Canc Res, Seattle, WA USA
[3] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [1] ROR1-specific CAR for neuroblastoma using sleeping beauty-modified t cells.
    Tejada, Fiorela Natali Hernandez
    Najjar, Amer
    Guerrero, Alan D.
    Flores, Leo G.
    Singh, Harjeet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] CD8+ T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Specifically Recognize ROR1 Positive B Cell Tumors
    Hudecek, Michael
    Schmitt, Thomas M.
    Baskar, Sivasubramanian
    Chang, Wen-Chung
    Maloney, David G.
    Jensen, Michael C.
    Rader, Christoph M.
    Riddell, Stanley
    BLOOD, 2009, 114 (22) : 383 - 383
  • [3] SUPERIOR ANTI-TUMOR EFFICACY OF CD4+CAR-T CELLS IN HEMATOLOGICAL MALIGNANCIES
    Chen, Q.
    Wang, L.
    Sedloev, D.
    Scheller, M.
    Unglaub, J.
    Schmitt, A.
    Mueller-Tidow, C.
    Schmitt, M.
    Sauer, T.
    HUMAN GENE THERAPY, 2023, 34 (21-22) : A14 - A14
  • [4] SUPERIOR ANTI-TUMOR EFFICACY OF CD4+CAR-T CELLS IN HEMATOLOGICAL MALIGNANCIES
    Chen, Qian
    Wang, Lei
    Lin, Min
    Sedloev, David
    Yao, Hao
    Scheller, Marina
    Eckstein, Volker
    Hofmann, Stefanie
    Han, Huixiu
    Ding, Yuntian
    Keib, Anna
    Jiang, Genqiao
    Hoffmann, Dominik
    Heilmann, Hannes
    Unglaub, Julia
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Schmitt, Michael
    Sauer, Tim
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 224 - 225
  • [5] IGF1R-and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
    Huang, Xin
    Park, Haein
    Greene, Joseph
    Pao, James
    Mulvey, Erin
    Zhou, Sophia X.
    Albert, Catherine M.
    Moy, Fred
    Sachdev, Deepali
    Yee, Douglas
    Rader, Christoph
    Hamby, Carl V.
    Loeb, David M.
    Cairo, Mitchell S.
    Zhou, Xianzheng
    PLOS ONE, 2015, 10 (07):
  • [6] Phase I study of immunotherapy for advanced ROR1+malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells.
    Specht, Jennifer M.
    Lee, Sylvia
    Turtle, Cameron
    Berger, Carolina
    Veatch, Josh
    Gooley, Ted
    Mullane, Erin
    Chaney, Colette
    Riddell, Stanley
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [7] Anti-ROR1 CAR-T cells: Architecture and performance
    Osorio-Rodriguez, Daniel Andres
    Camacho, Bernardo Armando
    Ramirez-Segura, Cesar
    FRONTIERS IN MEDICINE, 2023, 10
  • [8] The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
    Hudecek, Michael
    Schmitt, Thomas M.
    Baskar, Sivasubramanian
    Lupo-Stanghellini, Maria Teresa
    Nishida, Tetsuya
    Yamamoto, Tori N.
    Bleakley, Marie
    Turtle, Cameron J.
    Chang, Wen-Chung
    Greisman, Harvey A.
    Wood, Brent
    Maloney, David G.
    Jensen, Michael C.
    Rader, Christoph
    Riddell, Stanley R.
    BLOOD, 2010, 116 (22) : 4532 - 4541
  • [9] Generation and preclinical evaluation of a novel ROR1-specific CAR T-cells against chronic lymphocytic leukemia
    Hasan, Md Kamrul
    Oh, Christopher
    Girgis, Christina
    Widhopf, George
    Prussak, Charles
    Kipps, Thomas
    LEUKEMIA & LYMPHOMA, 2023, 64 : S195 - S195
  • [10] Engineered T cells modified with a high-affinity ROR1-CAR confer superior anti-tumor reactivity in vitro and in a mouse lymphoma model
    Hudecek, M.
    Kosasih, P.
    Yang, J.
    Einsele, H.
    Jensen, M. C.
    Rader, C.
    Riddell, S. R.
    ONKOLOGIE, 2012, 35 : 191 - 191
12345